Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats

European Journal of Pharmacology

Volumn 510, Issue 1-2, 2005, Pages 121-126

  Yatsu, Takeyuki ^a   Aoki, Motonori ^a   Tanaka, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Dopamine D1 like receptor; Nephrosis; Proteinuria; Puromycin aminonucleoside; Zelandopam

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; PREDNISOLONE; PUROMYCIN AMINONUCLEOSIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ZELANDOPAM;

ANIMAL MODEL; ARTICLE; ATTENUATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SELECTIVITY; FEMALE; LOW DRUG DOSE; NEPHROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; WEIGHT REDUCTION;

EID: 14644386803     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.01.024     Document Type: Article

References (45)

1. 3H]-SCH 23390 as a ligand J. Auton. Pharmacol. 10 1990 373 383
2. S. Anderson, J.R. Diamond, M.J. Karnovsky, and B.M. Brenner Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome J. Clin. Invest. 82 1988 1757 1768
3. H.L. Barnett, C.M. Edelmann Jr., and I. Greifer The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone J. Pediatr. 98 1981 561 564
4. M.P. Bohrer, C. Baylis, C.R. Robertson, B.M. Brenner, J.L. Troy, and W.T. Willis Mechanisms of the puromycin-induced defects in the transglomerular passage of water and macromolecules J. Clin. Invest. 60 1977 152 161
5. J.C. Chan, C.S. Cockram, M.G. Nicholls, C.K. Cheung, and R. Swaminathan Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis BMJ 305 1992 981 985
6. M.I. Christie, and G.W. Smith Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam J. Pharmacol. Exp. Ther. 268 1994 565 570
7. L. Davidsohn, and J.B. Henry Clinical diagnosis by laboratory methods 14th ed. 1969 W.B. Saunders Philadelphia 48
8. A. Drukker, and A.A. Eddy Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome J. Am. Soc. Nephrol. 9 1998 243 251
9. A.A. Eddy, and A.F. Michael Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis Kidney Int. 33 1988 14 23
10. A.A. Eddy, L. McCulloch, E. Liu, and J. Adams A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome Am. J. Pathol. 138 1991 1111 1123
11. G.M. Eisenbach, J.B. Liew, J.W. Boylan, N. Manz, and P. Muir Effect of angiotensin on the filtration of protein in the rat kidney: a micropuncture study Kidney Int. 8 1975 80 87
12. C.M. Erley, U. Harrer, B.K. Kramer, and T. Risler Renal hemodynamics and reduction of proteinuria by a vasodilating beta blocker versus an ACE inhibitor Kidney Int. 41 1992 1297 1303
13. R.T. Gansevoort, D. de Zeeuw, and P.E. de Jong Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 45 1994 861 867
14. L.I. Goldberg, and S.I. Rajfer Dopamine receptors: applications in clinical cardiology Circulation 72 1985 245 248
15. D. Gomez-Garre, R. Largo, N. Tejera, J. Fortes, F. Manzarbeitia, and J. Egido Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1 Hypertension 37 2001 1171 1178
16. K.P. Harris, J.B. Lefkowith, S. Klahr, and G.F. Schreiner Essential fatty acid deficiency ameliorates acute renal dysfunction in the rat after the administration of the aminonucleoside of puromycin J. Clin. Invest. 86 1990 1115 1123
17. T. Hirano, J.C. Mamo, S. Nagano, and T. Sugisaki The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside- induced nephrotic rats Nephron 58 1991 95 100
18. I. Ichikawa, H.G. Rennke, J.R. Hoyer, K.F. Badr, N. Schor, J.L. Troy, C.P. Lechene, and B.M. Brenner Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome J. Clin. Invest. 71 1983 91 103
19. S. Inokuchi, I. Shirato, N. Kobayashi, H. Koide, Y. Tomino, and T. Sakai Re-evaluation of foot process effacement in acute puromycin aminonucleoside nephrosis Kidney Int. 50 1996 1278 1287
20. D.K. Jorkasky, P. Audet, N. Shusterman, B. Ilson, D. Dafoe, D. Hedrich, and R.M. Stote Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients Am. J. Kidney Dis. 19 1992 567 572
21. 3 integrin-mediated podocyte shape by superoxide dismutase in the puromycin aminonucleoside nephrosis rat Am. J. Kidney Dis. 35 2000 1175 1185
22. J.E. Lachowicz, and D.R. Sibley Molecular characteristics of mammalian dopamine receptors Pharmacol. Toxicol. 81 1997 105 113
23. W. Lathem Renal circulatory dynamics and urinary protein excretion during infusion of l-norepinephrine and l-epinephrine in patients with renal diseases J. Clin. Invest. 36 1957 1457 1465
24. F. Locatelli, L.D. Vecchio, and P. Pozzoni The importance of early detection of chronic kidney disease Nephrol. Dial. Transplant. 17 Suppl. 11 2002 2 7
25. M.F. Lokhandwala, and F. Amenta Anatomical distribution and function of dopamine receptors in the kidney FASEB J. 5 1991 3023 3030
26. H.S. Mackenzie, and B.M. Brenner Current strategies for retarding progression of renal disease Am. J. Kidney Dis. 31 1998 161 170
27. I.G. McPherson, and D.W. Everard Serum albumin estimation: modification of the bromocresol green method Clin. Chim. Acta 37 1972 117 121
28. M.B. Murphy, C. Murray, and G.D. Shorten Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension New Engl. J. Med. 345 2001 1548 1557
29. T. Nakamura, I. Ebihara, M. Fukui, Y. Tomino, and H. Koide Effects of methylprednisolone on glomerular and medullary mRNA levels for extracellular matrices in puromycin aminonucleoside nephrosis Kidney Int. 40 1991 874 881
30. M. Nakayama, R. Katafuchi, T. Yanase, K. Ikeda, H. Tanaka, and S. Fujimi Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome Am. J. Kidney Dis. 39 2002 503 512
31. A.J. Nichols, P.F. Koster, D.P. Brooks, and R.R. Ruffolo Jr. Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog J. Pharmacol. Exp. Ther. 260 1992 269 274
32. G. Remuzzi, and T. Bertani Pathophysiology of progressive nephropathies N. Engl. J. Med. 339 1998 1448 1456
33. G. Remuzzi, P. Ruggenenti, and A. Benigni Understanding the nature of renal disease progression Kidney Int. 51 1997 2 15
34. P. Ruggenenti, A. Perna, L. Mosconi, M. Matalone, G. Garini, M. Salvadori, C. Zoccali, F. Scolari, Q. Maggiore, G. Tognoni, and G. Remuzzi Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 1997 1857 1863
35. G.B. Ryan, and M.J. Karnovsky An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis Kidney Int. 8 1975 219 232
36. 1) agonist, YM435 J. Pharmacol. Exp. Ther. 264 1993 1154 1159
37. J.A. Tumlin, A. Wang, P.T. Murray, and V.S. Mathur Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy Am. Heart J. 143 2002 894 903
38. S.J. Vyas, S. Apparsundaram, A. Ricci, F. Amenta, and M.F. Lokhandwala Biochemical, autoradiographic and pharmacological evidence for the involvement of tubular DA-1 receptors in the natriuretic response to dopexamine hydrochloride Naunyn-Schmiedeberg's Arch. Pharmacol. 343 1991 21 30
39. 1 receptor agonist activity of YM435 in the canine renal vasculature Gen. Pharmacol. 29 1997 229 232
40. 1 receptor agonist, in anesthetized dogs J. Cardiovasc. Pharmacol. 29 1997 382 388
41. 1 receptor agonist, in anesthetized dogs Eur. J. Pharmacol. 322 1997 45 53
42. 1 receptor agonist, in a canine model of ischemic acute renal failure Gen. Pharmacol. 31 1998 803 807
43. T. Yatsu, M. Aoki, and O. Inagaki Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats Eur. J. Pharmacol. 461 2003 191 195
44. T. Yatsu, M. Sanagi, A. Fujimori, Y. Tomura, K. Hayashi, M. Tanahashi, and O. Inagaki Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reduction Pharmacol. Res. 47 2003 243 252
45. T. Yatsu, M. Aoki, W. Uchida, and O. Inagaki Comparison between YM099 and captopril in rats with renal mass reduction-induced progressive renal disease Biol. Pharm. Bull. 28 2005 367 369